Theralink® Technologies Achieves Major Milestone:
Post# of 110
(Total Views: 366)
Posted On: 03/29/2021 4:10:40 PM
Theralink® Technologies Achieves Major Milestone: California Clinical and Public Health License for its Golden, CO Laboratory
DENVER , March 29, 2021 /PRNewswire/ -- Theralink Technologies, Inc. (OTC: OBMP), a precision medicine and molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical and Public Health License from the State of California for its Golden, Colorado laboratory, effective March 11th, 2021 .
The CLIA program is put in place by the Centers for Medicare & Medicaid Services (CMS) to regulate laboratories that test human specimens. The results of the California CLIA License allow Theralink to accept and perform testing on human specimens from California . The California Clinical and Public Health License survey showed that all CLIA Condition-level requirements were met, adhering to the highest standards in the industry.
"We are thrilled to receive the California Clinical and Public Health License for our Golden, CO laboratory as this was truly a team effort. Receiving the California licensure is a key step in our growth strategy as we plan to expand our testing capabilities and uncover key insights that may improve cancer treatment for breast cancer patients," said Mick Ruxin , M.D., President & CEO of Theralink Technologies, Inc. "With the Clinical and Public Health License from the State of California , we expect to begin receiving, testing and billing for patient's breast cancer tumor specimens in California in Q2 2021."
https://investorshangout.com/recentnews/OBMP#ixzz6qX9H3ntW
DENVER , March 29, 2021 /PRNewswire/ -- Theralink Technologies, Inc. (OTC: OBMP), a precision medicine and molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical and Public Health License from the State of California for its Golden, Colorado laboratory, effective March 11th, 2021 .
The CLIA program is put in place by the Centers for Medicare & Medicaid Services (CMS) to regulate laboratories that test human specimens. The results of the California CLIA License allow Theralink to accept and perform testing on human specimens from California . The California Clinical and Public Health License survey showed that all CLIA Condition-level requirements were met, adhering to the highest standards in the industry.
"We are thrilled to receive the California Clinical and Public Health License for our Golden, CO laboratory as this was truly a team effort. Receiving the California licensure is a key step in our growth strategy as we plan to expand our testing capabilities and uncover key insights that may improve cancer treatment for breast cancer patients," said Mick Ruxin , M.D., President & CEO of Theralink Technologies, Inc. "With the Clinical and Public Health License from the State of California , we expect to begin receiving, testing and billing for patient's breast cancer tumor specimens in California in Q2 2021."
https://investorshangout.com/recentnews/OBMP#ixzz6qX9H3ntW
(0)
(0)